Jeong H Yun1, Andrew Lamb2, Robert Chase2, Dave Singh3, Margaret M Parker4, Aabida Saferali4, Jørgen Vestbo5, Ruth Tal-Singer6, Peter J Castaldi4, Edwin K Silverman1, Craig P Hersh7. 1. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Mass; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. 2. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Mass. 3. University of Manchester, Manchester, United Kingdom. 4. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. 5. University of Manchester, Manchester, United Kingdom; NIHR Manchester Biomedical Research Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom. 6. GlaxoSmithKline R&D, King of Prussia, Pa. 7. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Mass; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. Electronic address: craig.hersh@channing.harvard.edu.
Abstract
BACKGROUND: Eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) is associated with exacerbations and responsivity to steroids, suggesting potential shared mechanisms with eosinophilic asthma. However, there is no consistent blood eosinophil count that has been used to define the increased exacerbation risk. OBJECTIVE: We sought to investigate blood eosinophil counts associated with exacerbation risk in patients with COPD. METHODS: Blood eosinophil counts and exacerbation risk were analyzed in patients with moderate-to-severe COPD by using 2 independent studies of former and current smokers with longitudinal data. The Genetic Epidemiology of COPD (COPDGene) study was analyzed for discovery (n = 1,553), and the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study was analyzed for validation (n = 1,895). A subset of the ECLIPSE study subjects were used to assess the stability of blood eosinophil counts over time. RESULTS: COPD exacerbation risk increased with higher eosinophil counts. An eosinophil count threshold of 300 cells/μL or greater showed adjusted incidence rate ratios for exacerbations of 1.32 in the COPDGene study (95% CI, 1.10-1.63). The cutoff of 300 cells/μL or greater was validated for prospective risk of exacerbation in the ECLIPSE study, with adjusted incidence rate ratios of 1.22 (95% CI, 1.06-1.41) using 3-year follow-up data. Stratified analysis confirmed that the increased exacerbation risk associated with an eosinophil count of 300 cells/μL or greater was driven by subjects with a history of frequent exacerbations in both the COPDGene and ECLIPSE studies. CONCLUSIONS: Patients with moderate-to-severe COPD and blood eosinophil counts of 300 cells/μL or greater had an increased risk exacerbations in the COPDGene study, which was prospectively validated in the ECLIPSE study.
BACKGROUND:Eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) is associated with exacerbations and responsivity to steroids, suggesting potential shared mechanisms with eosinophilic asthma. However, there is no consistent blood eosinophil count that has been used to define the increased exacerbation risk. OBJECTIVE: We sought to investigate blood eosinophil counts associated with exacerbation risk in patients with COPD. METHODS: Blood eosinophil counts and exacerbation risk were analyzed in patients with moderate-to-severe COPD by using 2 independent studies of former and current smokers with longitudinal data. The Genetic Epidemiology of COPD (COPDGene) study was analyzed for discovery (n = 1,553), and the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study was analyzed for validation (n = 1,895). A subset of the ECLIPSE study subjects were used to assess the stability of blood eosinophil counts over time. RESULTS: COPD exacerbation risk increased with higher eosinophil counts. An eosinophil count threshold of 300 cells/μL or greater showed adjusted incidence rate ratios for exacerbations of 1.32 in the COPDGene study (95% CI, 1.10-1.63). The cutoff of 300 cells/μL or greater was validated for prospective risk of exacerbation in the ECLIPSE study, with adjusted incidence rate ratios of 1.22 (95% CI, 1.06-1.41) using 3-year follow-up data. Stratified analysis confirmed that the increased exacerbation risk associated with an eosinophil count of 300 cells/μL or greater was driven by subjects with a history of frequent exacerbations in both the COPDGene and ECLIPSE studies. CONCLUSIONS:Patients with moderate-to-severe COPD and blood eosinophil counts of 300 cells/μL or greater had an increased risk exacerbations in the COPDGene study, which was prospectively validated in the ECLIPSE study.
Authors: John R Hurst; Jørgen Vestbo; Antonio Anzueto; Nicholas Locantore; Hana Müllerova; Ruth Tal-Singer; Bruce Miller; David A Lomas; Alvar Agusti; William Macnee; Peter Calverley; Stephen Rennard; Emiel F M Wouters; Jadwiga A Wedzicha Journal: N Engl J Med Date: 2010-09-16 Impact factor: 91.245
Authors: E Pizzichini; M M Pizzichini; A Efthimiadis; S Evans; M M Morris; D Squillace; G J Gleich; J Dolovich; F E Hargreave Journal: Am J Respir Crit Care Med Date: 1996-08 Impact factor: 21.405
Authors: Jeffrey I Stewart; Sarah Moyle; Gerard J Criner; Carla Wilson; Ron Tanner; Russell P Bowler; James D Crapo; Robert K Zeldin; Barry J Make; Elizabeth A Regan Journal: COPD Date: 2012-06-07 Impact factor: 2.409
Authors: David H Au; Christopher L Bryson; Jason W Chien; Haili Sun; Edmunds M Udris; Laura E Evans; Katharine A Bradley Journal: J Gen Intern Med Date: 2009-02-05 Impact factor: 5.128
Authors: Mona Bafadhel; Susan McKenna; Sarah Terry; Vijay Mistry; Carlene Reid; Pranabashis Haldar; Margaret McCormick; Koirobi Haldar; Tatiana Kebadze; Annelyse Duvoix; Kerstin Lindblad; Hemu Patel; Paul Rugman; Paul Dodson; Martin Jenkins; Michael Saunders; Paul Newbold; Ruth H Green; Per Venge; David A Lomas; Michael R Barer; Sebastian L Johnston; Ian D Pavord; Christopher E Brightling Journal: Am J Respir Crit Care Med Date: 2011-09-15 Impact factor: 21.405
Authors: Megan Hardin; Edwin K Silverman; R Graham Barr; Nadia N Hansel; Joyce D Schroeder; Barry J Make; James D Crapo; Craig P Hersh Journal: Respir Res Date: 2011-09-27
Authors: Jeong H Yun; Robert Chase; Margaret M Parker; Aabida Saferali; Peter J Castaldi; Edwin K Silverman; Craig P Hersh Journal: Am J Respir Cell Mol Biol Date: 2019-09 Impact factor: 6.914
Authors: Peter J Castaldi; Adel Boueiz; Jeong Yun; Raul San Jose Estepar; James C Ross; George Washko; Michael H Cho; Craig P Hersh; Gregory L Kinney; Kendra A Young; Elizabeth A Regan; David A Lynch; Gerald J Criner; Jennifer G Dy; Stephen I Rennard; Richard Casaburi; Barry J Make; James Crapo; Edwin K Silverman; John E Hokanson Journal: Chest Date: 2019-12-28 Impact factor: 9.410
Authors: Bashar N Alzghoul; Mohammad As Sayaideh; Brian F Moreno; Saminder K Singh; Ayoub Innabi; Raju Reddy; Eric S Papierniak; Hassan M Alnuaimat Journal: ERJ Open Res Date: 2021-03-08
Authors: Chunrui Zou; Frank Li; Jiwoong Choi; Babak Haghighi; Sanghun Choi; Prathish K Rajaraman; Alejandro P Comellas; John D Newell; Chang Hyun Lee; R Graham Barr; Eugene Bleecker; Christopher B Cooper; David Couper; Meilan Han; Nadia N Hansel; Richard E Kanner; Ella A Kazerooni; Eric C Kleerup; Fernando J Martinez; Wanda O'Neal; Robert Paine; Stephen I Rennard; Benjamin M Smith; Prescott G Woodruff; Eirc A Hoffman; Ching-Long Lin Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-05-31